OncoMatch/Clinical Trials/NCT07221357
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Is NCT07221357 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments for untreated, unresectable, or metastatic colorectal cancer.
Treatment: Pumitamig · FOLFOX · FOLFIRI · Bevacizumab · CAPOX — The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MMR deficient
no known presence of mismatch repair deficient (dMMR) colorectal cancer (CRC) per historical results (a validated test should be used)
Required: MSI high
no known presence of...microsatellite instability-high (MSI-H) colorectal cancer (CRC) per historical results (a validated test should be used)
Required: BRAF V600E
no known presence of the gene that encodes the protein B-Raf (BRAF) V600E mutation per local testing
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: anti-PD-1 therapy
prior systemic treatment with an anti-PD-1
Cannot have received: anti-PD-L1 therapy
prior systemic treatment with an anti-programmed death (ligand)-1 (PD-L1)
Cannot have received: anti-PD-L2 therapy
prior systemic treatment with an anti-PD-L2
Cannot have received: CD137 agonist
prior systemic treatment with...CD137 agonists
Cannot have received: anti-CTLA-4 therapy
prior systemic treatment with...anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody
Cannot have received: checkpoint inhibitor
any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways
Cannot have received: cytotoxic chemotherapy
prior systemic treatment with...chemotherapy
Lab requirements
Cardiac function
no significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis or cerebrovascular accident within 6 months prior to randomization, uncontrolled hypertension (≥ 160 systolic, ≥ 100 diastolic mm Hg) despite optimal medical management, or congenital long QT syndrome
Participant must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis or cerebrovascular accident within 6 months prior to randomization, uncontrolled hypertension (≥ 160 systolic, ≥ 100 diastolic mm Hg) despite optimal medical management, or congenital long QT syndrome.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0428 · Tucson, Arizona
- Local Institution - 0432 · Springdale, Arkansas
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
- Local Institution - 0345 · Orange, California
- Local Institution - 0317 · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify